


Stock Number: 6767



wittrom
Your Health Partner

Wiltrom Co., Ltd

Safe Harbor Notice

Except for historical information set forth herein, this presentation contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied by such statements. Investors shall assess the potential impact of uncertainties and conduct risk control.

Outline



Company Profile and Business Development

Operational and Financial Overview

Future Outlook and Key Takeaways

COMPANY PROFILE

Minimally Invasive Spinal Surgery Platform - Comprehensive Care Solutions

Company Portfolio

- Establish: Dec. 2009 (A spin-off company from ITRI)
- Paid in Capital: NTD\$ 391,836,300
- Subsidiary: Wiltrom Inc.
- Employee: 55
- A company devoted to MIS spinal surgery with a completed product line

RD & RA

- The company has 50 patents across four major product lines.
- The company has strong manufacturing know-how.
- Quality certification: QMS, ISO 13485, Taiwan-QMS, BGMP
- Regulatory certification: TFDA, FDA, CE, NMPA

Sales and BD

- Sales to 66% of total hospitals in Taiwan (cover 100% medical centers)
- Sales in more than 20 countries and signed distributors over 50 accounts
- Tripod-Fix has accumulated over 5000 implants (sales to 65% medical centers in Taiwan)

WILTROM'S GLOBAL SALES TERRITORY

Actively Expand Overseas Markets

Markert Size US\$8.2B


Spinal Fusion



Interbody Fusion System




Bone Graft Substitute




Markert Size US\$1.15B

Vertebral Augmentation System Tripod-Fix



Markert Size US\$1.32B


Bone Cement



Tripod-Fix

First expandable device
focused on the
“Wedge Fracture Treatment”

85% of VCFs are Wedge Fractures*




One-piece design




3D Triangular Pyramid


Vertebral
compression
fracture
(VCFs)



Expansion



Cement
injection



Complete the surgery within 30 min

*Ref. The Spine Journal , 2015, 15, 281–2895

MARKET GROWTH MOMENTUM

Driven by Tripod-Fix and Strategic Expansion in Europe

Market Share Target :

- >10% Market Share in Germany (*Europe's Largest Market*)
- ~10% Market Share Across Europe

Extensive European Distribution Network

- Direct Sales (*planning*) : Germany
- Distributors : Covering 11 European countries

Direct & Hybrid-Direct Sales

Direct Sales:
in selected country
(with partner)

Hybrid Direct:
local service team to support distributor

Marketing Activity

Congress
Exhibition
Workshop

Digital Marketing

Evidence-based Marketing

KOL Endorsement

Clinical Study & Publication


Medical Guideline



Tripod-Fix GLOBAL GROWTH POTENTIAL

85% Growth in 2024 and Anticipate Robust Growth in 2025

Tripod-Fix GLOBAL SALES GROWTH TREND



EUROSPINE 2024 Tripod-Fix CLINICAL INSIGHT SYMPOSIUM

Vienna, Austria/ Oct. 3rd : 3 KOL Speakers from Germany and Taiwan and 50 participants



Prof. Robert Pflugmacher

Chief doctor, Clinic for
Orthopaedics, Krankenhaus
Mechernich

▪ Mechernich, Germany



Prof. Andreas Kurth

Director Center of Orthopedic
and Trauma Surgery. Surgeon
at Dr. Baron and colleagues,
Frankfurt / Main

▪ Frankfurt, Germany



Prof. Cheng-Li Lin

Director of Spinal Division,
National Cheng Kung
University Hospital

▪ Tainan, Taiwan



EUROSPINE 2024 Tripod-Fix CLINICAL INSIGHTS SYMPOSIUM

Prof. Dr. Pflugmacher Highlighting Key Benefit of Tripod-Fix



- 2023 Top European Surgeon Award
- Stryker SpineJack (SAKOS) study PI
- Wiltrom PMCF study PI
- The pioneer in Europe for balloon kyphoplasty
- The most experienced Kyphoplasty surgeons
- 45 Tripod-Fix surgical cases since Feb. 2024
- **Recommend Tripod-Fix for its benefit:**
 - ✓ **Height restoration at the anterior end of fractured vertebrae**
 - ✓ **Treating wedge vertebral fractures**



FOCUS
TOP
MEDIZINER
2023
WIRBEL-SÄULEN-CHIRURGIE
FACT JFIELD

kkhm
Krankenhaus
Mechernich

Wirbelsäulenzentrum Eifel

Prof. Dr. med. R. Pflugmacher
Wirbelsäulenchirurgie
Spezielle orthopädische Chirurgie
Spezielle Unfallchirurgie
Osteologie DVO

O. Soliman
Leitender Abteilungsarzt
St. Elisabeth-Strasse 2-6, 53894 Mechernich
E-Mail: sekretariat.orthopaedie@kkhm.de

Chefsekretariat: 02443/17-1751
Telefax: 02443/17-1752
Ambulanz: 02443/17-1753
Telefax: 02443/17-1781

June 24, 2024

To Whom It May Concern,

I served as a head of spinal orthopaedics clinic and polyclinic in University Hospital Bonn, senior consultant in University Hospital Bonn, and currently practices in Krankenhaus Mechernich as the chief surgeon in Germany. My practical field focuses on the spinal surgery with over 20-year experience, including several participations in clinical trials and usability consultations for innovative orthopedical medical devices. I was invited and participate the European post market clinical follow up (PMCF) of Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix) sponsored by Wiltrom Co., Ltd. since January 2024.

Tripod-Fix is intended to be used for the reduction and treatment of spinal fractures in the thoracic and/or lumbar spine from T6-L5 caused mainly by osteoporosis. In the ongoing European PMCF study, over 15 subjects were enrolled and more than 25 devices have been implanted in last three months after the study initiation. Pursuant to the well-organized data, most of the treated subjects had significant improvements upon their Visual Analogue Scale for pain (VAS Pain) and Oswestry Disability Index (ODI). As a previous SpineJack System (SpineJack) user, I agree with the design of Tripod-Fix, which specifically targets the unmet need of treating wedge vertebral fractures, the most common type in osteoporotic vertebral compression fracture (OVCF). I am also impressed with the significant height restoration of Tripod-Fix, particularly at the anterior end of fractured vertebrae. The result strengthens my confidence to reduce the chance of occurrence of refractures or adjacent level fractures in the subjects even though the long-term data are still under collection.


Best regards,

Prof. Dr. med. *R. Pflugmacher*
Chief Surgeon

Träger Krankenhaus Mechernich GmbH
Vertretender Geschäftsführer: Torsten Dietler | Geschäftsführer: Martin Mies
Bankverbindung: Kreissparkasse Eifelkreis: IBAN DE88 3629 0110 0003 3000 50, BIC WELADED3333
Volksbank Eifelkreis: IBAN DE81 8428 0082 0000 9100 10, BIC GENODE33119
Postbank AG: IBAN DE44 2512 0500 0002 0240 00, BIC PBNK3333000
Sitz der Gesellschaft: Mechernich | Eingetragen beim Amtsgericht Bonn HRB-Nr. 10852
www.krankenhaus-mechernich.de | info@rankenhaus-mechernich.de

EUROSPINE 2024 Tripod-Fix CLINICAL INSIGHT SYMPOSIUM

Vienna, Austria: Featured 3 KOL Speakers from Germany and Taiwan



Prof. Dr. Pflugmacher :

“Using Tripod-Fix you have more opportunities and in several fractures you have a better height restoration.”

The studies have shown, I mean we're still in the study mode, but from my clinical experience I would recommend using this one.”

Tripod-Fix First Large-Scale Cadaver Workshop in Europe

July 1st, Dr. Marcia Demonstrated in Verona, Italy and Shared Key Advantages



Dr. Stefano Marcia


- Stryker SpineJack (SAKOS) PI
- Head of Radiology at the SS. Trinità Hospital
- Specialize in the interventional radiology, spine radiology, and pain management
- Expertise includes percutaneous minimally invasive treatments

30 Participants from distributors of 6 European countries




Tripod-Fix SUPERIOR TO SPINEJACK IN ANTERIOR RESTORATION

One of The Best Third-gen Vertebral Augmentation




85% of VCFs are Wedge Fractures



Stryker acquired Vexim for \$191 million in 2017

Orthop Traumatol Surg Res. 2015;101(7):857–859
Osteoporosis international 2016; 27: 2047-2055
Appl. Sci. 2022, 12(19), 10165

Outline




Company Profile and Business Development

Operational and Financial Overview

Future Outlook and Key Takeaways

Q1-Q3/2023 FINANCIAL RESULTS

Year-on-Year Revenue Growth



(In Thousands of New Taiwan Dollars)

* Clinical expenses will start in 2023 and peak in 2024, It is expected to end in 2025


ACCOUNT	Q1~Q3/2023	Q1~Q3/2024	DIFF	YOY
NET OPERATING REVENUE	210,540	240,364	29,824	14.2%
NET OPERATING INCOME(LOSS)	(9,658)	(34,654)	(24,996)	258.8%
NET NON-OPERATING INCOME(EXPENSE)	18,370	1,270	(17,100)	-93.1%
INCOME(LOSS) FROM CONTINUING OPERATION	8,540	(33,383)	(41,923)	-490.9%
EARNINGS PER SHARE (NT\$)	0.29	(1.15)	(1.44)	-496.6%

※ We have seen sustained growth in Sales; However, due to current clinical expenses*, the loss has increased compared to the same period last year. Non-operating income and expenses are mainly gains on financial assets measured at fair value through profit or loss.

OPERATING REVENUE IN RECENT YEARS

Steady Revenue Growth


(In Thousands of New Taiwan Dollars)



EXPORT REVENUE GROWTH RATE OF 122%


Continued to Boost Overseas Revenue

(In Thousands of New Taiwan Dollars)



- Overall Overseas Revenue Increased by \$26,537 Compared to the Same Period Last Year (Year-on-Year Growth of 122%)

Outline



Company Profile and Business Development

Operational and Financial Overview

Future Outlook and Key Takeaways

Completed a private fundraising of NT\$270 million on 11/20/2024



Strategic Lead Investors:

- Taiwan/U.S. medical industry cultivated for 10+ years
- Grasp industrial chain dynamics through investment



Original Shareholders (Long-term Support)

- Deep technical accumulation in medical material manufacturing
- Focus on high-end precision product R&D and manufacturing

Expand the product line portfolio, continue to screen star products to maintain the company's growth momentum

Grow the EU market and open up new markets in the United States and Japan

Optimize the cost structure, and increase revenue and profitability with high technology, high gross profit and high growth (three high)

Conclusion

- Tripod-Fix global sales increased by 85% compared to last year
- Overseas revenue sales increased by 122% compared to last year
- We will continue to screen the three high-star products and establish solid local channel networking to drive the rapid growth of revenue

Thank You

wittrom
Your Health Partner